- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 211/40 - Atomes d'oxygène
Détention brevets de la classe C07D 211/40
Brevets de cette classe: 123
Historique des publications depuis 10 ans
|
5
|
8
|
8
|
7
|
5
|
6
|
8
|
12
|
5
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| FMC Corporation | 816 |
5 |
| ChemoCentryx, Inc. | 356 |
4 |
| F. Hoffmann-La Roche AG | 7777 |
3 |
| AstraZeneca AB | 2841 |
3 |
| Amgen Inc. | 4492 |
3 |
| Shanghai Meiyue Biotech Development Co., Ltd. | 64 |
3 |
| Bristol-myers Squibb Company | 4756 |
2 |
| Board of Regents, The University of Texas System | 6225 |
2 |
| Amyris, Inc. | 369 |
2 |
| Athenex, Inc. | 25 |
2 |
| Jiangsu Hengyi Pharmaceutical Co., Ltd. | 389 |
2 |
| Neurocrine Biosciences, Inc. | 471 |
2 |
| Nippon Soda Co., Ltd. | 884 |
2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 736 |
2 |
| Sirna Therapeutics, Inc. | 97 |
2 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3034 |
2 |
| Idorsia Pharmaceuticals Ltd. | 332 |
2 |
| Theravance Biopharma R&D IP, LLC | 359 |
2 |
| Shanghai Meizer Pharmaceuticals Co., Ltd. | 13 |
2 |
| Vividion Therapeutics, Inc. | 46 |
2 |
| Autres propriétaires | 74 |